Impaired cholesterol efflux capacity of high-density lipoprotein isolated from interstitial fluid in type 2 diabetes mellitus - brief report

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 36, Issue 5, 2016, Pages 787-791

  Apro, Johanna ^a   Tietge, Uwe J F ^b   Dikkers, Arne ^b   Parini, Paolo ^a   Angelin, Bo ^a   Rudling, Mats ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

diabetes mellitus, type 2; extracellular fluid; high density lipoprotein cholesterol; low density lipoprotein cholesterol; macrophages

Indexed keywords

CHOLESTEROL ESTER; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOLIPID; TRIACYLGLYCEROL;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DIABETIC PATIENT; HUMAN; IN VITRO STUDY; INTERSTITIAL FLUID; LIPID COMPOSITION; MACROPHAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; PARTICLE SIZE; PRIORITY JOURNAL; BLOOD; CASE CONTROL STUDY; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; EXTRACELLULAR FLUID; ISOLATION AND PURIFICATION; METABOLISM; TIME FACTOR; TRANSPORT AT THE CELLULAR LEVEL;

BIOLOGICAL TRANSPORT; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; EXTRACELLULAR FLUID; HUMANS; TIME FACTORS;

EID: 84962109764     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.116.307385     Document Type: Article

References (30)

1. Mazzone T, Chait A, Plutzky J, Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. Lancet 2008 371 1800 1809. doi: 10.1016/S0140-6736(08)60768-0
2. Collins R, Armitage J, Parish S, Sleigh P, Peto R, Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003 361 2005 2016
3. Apro J, Parini P, Broijersén A, Angelin B, Rudling M, Levels of atherogenic lipoproteins are unexpectedly reduced in interstitial fluid from type 2 diabetes patients. J Lipid Res 2015 56 1633 1639. doi: 10.1194/jlr.P058842
4. Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, Patsch W, Atherosclerosis Risk in Communities Study Group Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2001 104 1108 1113
5. Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, Tomson J, Wallendszus K, Craig M, Jiang L, Collins R, Armitage J, Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 2014 371 203 212
6. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W, Niacin in patients with low hdl cholesterol levels receiving intensive statin therapy. N Engl J Med 2011 365 2255 2267
7. Schwartz GG, Olsson AG, Abt M, dal-OUTCOMES Investigators Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012 367 2089 2099. doi: 10.1056/NEJMoa1206797
8. Triolo M, Annema W, Dullaart RP, Tietge UJ, Assessing the functional properties of high-density lipoproteins: an emerging concept in cardiovascular research. Biomark Med 2013 7 457 472. doi: 10.2217/bmm.13.35
9. Rosenson RS, Brewer HB Jr, Davidson WS, Fayad ZA, Fuster V, Goldstein J, Hellerstein M, Jiang XC, Phillips MC, Rader DJ, Remaley AT, Rothblat GH, Tall AR, Yvan-Charvet L, Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation 2012 125 1905 1919. doi: 10.1161/CIRCULATIONAHA.111.066589
10. Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin KE, Neeland IJ, Yuhanna IS, Rader DR, de Lemos JA, Shaul PW, HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med 2014 371 2383 2393. doi: 10.1056/NEJMoa1409065
11. Syvänne M, Castro G, Dengremont C, De Geitere C, Jauhiainen M, Ehnholm C, Michelagnoli S, Franceschini G, Kahri J, Taskinen MR, Cholesterol efflux from Fu5AH hepatoma cells induced by plasma of subjects with or without coronary artery disease and non-insulin-dependent diabetes: importance of LpA-I:A-II particles and phospholipid transfer protein. Atherosclerosis 1996 127 245 253
12. Autran D, Attia N, Dedecjus M, Durlach V, Girard-Globa A, Postprandial reverse cholesterol transport in type 2 diabetic patients: effect of a lipid lowering treatment. Atherosclerosis 2000 153 453 460
13. Attia N, Nakbi A, Smaoui M, Chaaba R, Moulin P, Hammami S, Hamda KB, Chanussot F, Hammami M, Increased phospholipid transfer protein activity associated with the impaired cellular cholesterol efflux in type 2 diabetic subjects with coronary artery disease. Tohoku J Exp Med 2007 213 129 137
14. Zhou H, Tan KC, Shiu SW, Wong Y, Determinants of leukocyte adenosine triphosphate-binding cassette transporter G1 gene expression in type 2 diabetes mellitus. Metabolism 2008 57 1135 1140. doi: 10.1016/j.metabol.2008.03.020
15. Miller NE, Olszewski WL, Hattori H, Miller IP, Kujiraoka T, Oka T, Iwasaki T, Nanjee MN, Lipoprotein remodeling generates lipid-poor apolipoprotein A-I particles in human interstitial fluid. Am J Physiol Endocrinol Metab 2013 304 E321 E328. doi: 10.1152/ajpendo.00324.2012
16. Nanjee MN, Cooke CJ, Wong JS, Hamilton RL, Olszewski WL, Miller NE, Composition and ultrastructure of size subclasses of normal human peripheral lymph lipoproteins: quantification of cholesterol uptake by HDL in tissue fluids. J Lipid Res 2001 42 639 648
17. Nanjee MN, Cooke CJ, Garvin R, Semeria F, Lewis G, Olszewski WL, Miller NE, Intravenous apoA-I/lecithin discs increase pre-beta-HDL concentration in tissue fluid and stimulate reverse cholesterol transport in humans. J Lipid Res 2001 42 1586 1593
18. Triolo M, Annema W, de Boer JF, Tietge UJ, Dullaart RP, Simvastatin and bezafibrate increase cholesterol efflux in men with type 2 diabetes. Eur J Clin Invest 2014 44 240 248. doi: 10.1111/eci.12226
19. Dullaart RP, Annema W, de Boer JF, Tietge UJ, Pancreatic β-cell function relates positively to HDL functionality in well-controlled type 2 diabetes mellitus. Atherosclerosis 2012 222 567 573. doi: 10.1016/j.atherosclerosis.2012.03.037
20. Dullaart RP, van Tol A, Twenty four hour insulin infusion impairs the ability of plasma from healthy subjects and Type 2 diabetic patients to promote cellular cholesterol efflux. Atherosclerosis 2001 157 49 56
21. Low H, Hoang A, Forbes J, Thomas M, Lyons JG, Nestel P, Bach LA, Sviridov D, Advanced glycation end-products (AGEs) and functionality of reverse cholesterol transport in patients with type 2 diabetes and in mouse models. Diabetologia 2012 55 2513 2521. doi: 10.1007/s00125-012-2570-9
22. Guerin M, Egger P, Soudant C, Le Goff W, van Tol A, Dupuis R, Chapman MJ, Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux. Atherosclerosis 2002 163 287 296
23. Franceschini G, Calabresi L, Colombo C, Favari E, Bernini F, Sirtori CR, Effects of fenofibrate and simvastatin on HDL-related biomarkers in low-HDL patients. Atherosclerosis 2007 195 385 391. doi: 10.1016/j.atherosclerosis.2006.10.017
24. Sviridov D, Hoang A, Ooi E, Watts G, Barrett PH, Nestel P, Indices of reverse cholesterol transport in subjects with metabolic syndrome after treatment with rosuvastatin. Atherosclerosis 2008 197 732 739. doi: 10.1016/j.atherosclerosis.2007.07.007
25. Camont L, Lhomme M, Rached F, Le Goff W, Nègre-Salvayre A, Salvayre R, Calzada C, Lagarde M, Chapman MJ, Kontush A, Small, dense high-density lipoprotein-3 particles are enriched in negatively charged phospholipids: relevance to cellular cholesterol efflux, antioxidative, antithrombotic, anti-inflammatory, and antiapoptotic functionalities. Arterioscler Thromb Vasc Biol 2013 33 2715 2723. doi: 10.1161/ATVBAHA.113.301468
26. Du XM, Kim MJ, Hou L, Le Goff W, Chapman MJ, Van Eck M, Curtiss LK, Burnett JR, Cartland SP, Quinn CM, Kockx M, Kontush A, Rye KA, Kritharides L, Jessup W, HDL particle size is a critical determinant of ABCA1-mediated macrophage cellular cholesterol export. Circ Res 2015 116 1133 1142. doi: 10.1161/CIRCRESAHA.116.305485
27. Taskinen MR, Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003 46 733 749. doi: 10.1007/s00125-003-1111-y
28. Duell PB, Oram JF, Bierman EL, Nonenzymatic glycosylation of HDL and impaired HDL-receptor-mediated cholesterol efflux. Diabetes 1991 40 377 384
29. Fournier N, Paul JL, Atger V, Cogny A, Soni T, de la Llera-Moya M, Rothblat G, Moatti N, HDL phospholipid content and composition as a major factor determining cholesterol efflux capacity from Fu5AH cells to human serum. Arterioscler Thromb Vasc Biol 1997 17 2685 2691
30. Robert J, Lehner M, Frank S, Perisa D, von Eckardstein A, Rohrer L, Interleukin 6 stimulates endothelial binding and transport of high-density lipoprotein through induction of endothelial lipase. Arterioscler Thromb Vasc Biol 2013 33 2699 2706. doi: 10.1161/ATVBAHA.113.301363